Biagio Ricciuti, Thoracic Medical Oncologist at Dana Farber Cancer Institute, shared a post on X, about two articles that he and his collogues co-authored, adding:
“Excited to share our 2 new studies published today in The Lancet Oncology – one offering deeper insight into refining ICI for PD-L1–negative and STK11-mutant NSCLC, and the other exploring ICI vs BRAF/MEKi in BRAF V600E NSCLC.
These studies aren’t full answers – but we hope they help sharpen strategies and spark further progress in tailoring immunotherapy for NSCLCs historically seen as resistant.
Heartfelt thanks to the co-authors, patients, collaborators and reviewers who made this possible.”
Fawzi Abu Rous, Medical Oncologist at Henry Ford Health, shared this post on X, adding:
“Glad to have participated in the FRONT-BRAF study comparing immunotherapy with or without chemo to BRAF/MEK inhibitors in 1st line treatment of BRAF-mut NSCLC This is a highly relevant paper that can have immediate implications in the clinic!
Huge thanks to Biagio Ricciuti and Alessandro Di Federico for leading this effort and congrats to all co-authors!.”
Title: First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Authors: Alessandro Di Federico, Kaiwen Wang, Monica F. Chen, Adam A. Barsouk, Arianna Pagliaro, Lanyi N. Chen, Francesca R. Ogliari, Paul Stockhammer, Rajat Thawani, Shahm Raslan, Eleonora Gariazzo, Francesca Fusco, Grace M. Hambelton, Fabrizio Citarella, David Meyer, Mihaela Aldea, Andrea De Giglio, Joao V. Alessi, Federica Pecci, Francesco Gelsomino, Marcelo Corassa, Natalie I. Vokes, Xinan Wang, Dario de Biase, Fawzi Abu Rous, Phurin Areesawangkit, Omar Elghawy, Alessio Cortellini, Giulio Metro, Roberto Ferrara, Mark M. Awad, Aliyah Pabani, Joseph C. Murray, Federico Cappuzzo, Marina C. Garassino, Ibiayi Dagogo-Jack, Gregory Riely, Michael Grant, Benjamin O. Herzberg, Andrea Ardizzoni, David Planchard, Bruce E. Johnson, Corey J. Langer, Michael Offin, Marcelo V. Negrao, Biagio Ricciuti.
Read the full article on The Lancet Oncology.
Title: Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
Authors: Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, Andrea De Giglio, Francesca Lo Bianco, Federica Pecci, Joao V. Alessi, Xinan Wang, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Ferdinandos Skoulidis, Marina C. Garassino, Solange Peters, Mark M. Awad, Andrea Ardizzoni, Biagio Ricciuti
Read the full article on The Lancet Oncology.
Read more posts about NSCLC on OncoDaily.